In addition, more importance was placed on all molecular markers (MSI, KRAS and BRAF) and tumour markers (CEA, CA19.9, CA125) but to a lesser magnitude (i.e. < 10% difference from general cohort responses). The gene discussed is KRAS; the disease is neoplasm.